Sensus Healthcare Inc.
Sensus Healthcare, Inc. manufactures, distributes, and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sculptura product, a proprietary modulated robotic brachytherapy oncology therapy system that uses patented Beam Sculpting capabilities to treat various cancers during surgery; and Sentinel service program, which offers its customers protection for their systems. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons, eye shields, and disposable applicator tips, which are used to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.
IPO Year: 2016
Exchange: NASDAQ
Website: sensushealthcare.com
Recent Analyst Ratings for Sensus Healthcare Inc.
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/31/2025 | $18.00 | Buy | Lake Street |
11/15/2024 | $12.00 → $14.00 | Buy | Maxim Group |
3/3/2022 | $12.00 → $13.00 | Buy | HC Wainwright & Co. |
2/14/2022 | $10.00 → $12.00 | Buy | HC Wainwright & Co. |
12/2/2021 | $9.00 → $10.00 | Buy | HC Wainwright & Co. |
11/5/2021 | $7.00 → $9.00 | Buy | HC Wainwright & Co. |
8/6/2021 | $6.00 → $7.00 | Buy | HC Wainwright & Co. |
Sensus Healthcare Inc. Press Releases
Fastest customizable press release news feed in the world
Sensus Healthcare to Participate in the 37th Annual ROTH Conference
Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces it will be participating in Roth Capital's 37th Annual ROTH Conference, being held March 17-18 in Dana Point, California. Management will be holding one-on-one meetings with registered investors during the conference. Registered attendees who would like to schedule a meeting with Sensus Healthcare management should contact their ROTH representative or Tirth Patel at tpatel@allianceadvisors.com. About Sensus Healthcare Sensus Healthcare, Inc. is a global pioneer in the
Sensus Healthcare Buys Back Shares
Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces that the company has resumed purchasing shares of its common stock in open-market transactions under a $3.0 million share repurchase program approved by its Board of Directors and announced in August 2023. "We are implementing this program now as we view the repurchase of our common stock as a compelling opportunity at current prices," said Joe Sardano, Chairman and CEO of Sensus Healthcare. "We remain confident in our growth prospects and believe that returning capita
Sensus Healthcare Reports Fourth Quarter and Full Year 2024 Financial Results
Shipped a record 39 SRT systems during the quarter; revenues of $13.1 million Achieved fifth consecutive quarter of profitability; diluted EPS of $0.09 Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and 12 months ended December 31, 2024. Highlights include the following: Revenues were $13.1 million for the fourth quarter and $41.8 million for the year, up 4% and 71% respectively, compared with the prior year Net income
Sensus Healthcare to Present at The Microcap Conference 2025
Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J. Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities. Event: The Microcap Conference 2025 Location: Studio 2, Borgata Hotel Casino & Spa Date: Thursday, January 30, 2025 Time: 2:00 PM Eastern Ti
Sensus Healthcare to Report 2024 Fourth Quarter and Full Year Financial Results and Hold Business Update Conference Call on Wednesday, February 5, 2025
Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report financial results for the 2024 fourth quarter and full year on Wednesday, February 5, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and
Pompano Veterinary Oncology Partners with Sensus Healthcare to Provide First Superficial Radiotherapy Services in a Mobile Configuration
Full-service medical oncology practice to pioneer the use of SRT to treat companion animals for both home and veterinary clinic visits BOCA RATON, Fla, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, has partnered with Pompano Veterinary Oncology to pioneer the use of SRT to treat companion animals across South Florida via the use of a mobile van. Pompano Veterinary Oncology is a full-service mobile veterinary medical oncology practice specializing in feline and canine oncology, with the go
REVISED - Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter
This revised news release replaces the one issued on November 14, 2024, contains several non-financial changes throughout and removes the name of and references to a new customer, at the customer's request. The agreement with the new customer remains in effect. Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year ago Expects to have more than 50 IG-SRT Systems signed under the Fair Deal Agreement recurring-revenue program by the end of the year BOCA RATON, Fla, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializin
Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter
Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year agoSigned a Fair Deal Agreement with Platinum Dermatology, a leading dermatology network with 130 clinics across the U.S. Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and nine months ended September 30, 2
Sensus Healthcare to Host Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 14, 2024
BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 14, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones. Participants are encouraged to pre-register for the conference call using this link. Upon registration participants will receive a unique dial-in number that will permit them to bypass
Sensus Healthcare Sells SRT System to Providence Swedish Hospital
BOCA RATON, Fla., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces it has shipped an SRT system to Providence Swedish Hospital in Seattle. This sale represents the Company's latest success in generating interest in superficial radiotherapy (SRT) from community hospital oncology departments. Christopher Loiselle, M.D., Medical Director of Radiation Oncology at Swedish Cancer Institute at Providence Swedish, said, "Sensus' SRT system is a state-of-the-art system for optimal tre
Sensus Healthcare Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Lake Street initiated coverage on Sensus Healthcare with a new price target
Lake Street initiated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $18.00
Maxim Group reiterated coverage on Sensus Healthcare with a new price target
Maxim Group reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $14.00 from $12.00 previously
HC Wainwright & Co. reiterated coverage on Sensus Healthcare with a new price target
HC Wainwright & Co. reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $13.00 from $12.00 previously
HC Wainwright & Co. reiterated coverage on Sensus Healthcare with a new price target
HC Wainwright & Co. reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $12.00 from $10.00 previously
HC Wainwright & Co. reiterated coverage on Sensus Healthcare with a new price target
HC Wainwright & Co. reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $10.00 from $9.00 previously
HC Wainwright & Co. reiterated coverage on Sensus Healthcare with a new price target
HC Wainwright & Co. reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $9.00 from $7.00 previously
HC Wainwright & Co. reiterated coverage on Sensus Healthcare with a new price target
HC Wainwright & Co. reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $7.00 from $6.00 previously
HC Wainwright reiterated coverage on Sensus Healthcare with a new price target
HC Wainwright reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $6.00 from $4.00 previously
Roth Capital reiterated coverage on Sensus Healthcare with a new price target
Roth Capital reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $6.00 from $4.00 previously
HC Wainwright & Co. reiterated coverage on Sensus Healthcare with a new price target
HC Wainwright & Co. reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $6.00 from $4.00 previously
Sensus Healthcare Inc. Insider Purchases
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
CHIEF FINANCIAL OFFICER Rampolla Javier bought $2,981 worth of shares (501 units at $5.95), increasing direct ownership by 1% to 40,745 units (SEC Form 4)
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
PRESIDENT AND GENERAL COUNSEL Sardano Michael bought $5,950 worth of shares (1,000 units at $5.95), increasing direct ownership by 0.87% to 115,839 units (SEC Form 4)
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
Sensus Healthcare Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
CHIEF FINANCIAL OFFICER Rampolla Javier bought $2,981 worth of shares (501 units at $5.95), increasing direct ownership by 1% to 40,745 units (SEC Form 4)
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
PRESIDENT AND GENERAL COUNSEL Sardano Michael bought $5,950 worth of shares (1,000 units at $5.95), increasing direct ownership by 0.87% to 115,839 units (SEC Form 4)
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
Director Petrelli Anthony Benedict was granted 20,000 shares, increasing direct ownership by 43% to 66,466 units (SEC Form 4)
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
Director Mccall William H was granted 20,000 shares, increasing direct ownership by 200% to 30,000 units (SEC Form 4)
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
Director Cornish Megan was granted 20,000 shares, increasing direct ownership by 167% to 32,000 units (SEC Form 4)
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
PRESIDENT AND GENERAL COUNSEL Sardano Michael was granted 40,000 shares, increasing direct ownership by 53% to 114,839 units (SEC Form 4)
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
CHIEF FINANCIAL OFFICER Rampolla Javier covered exercise/tax liability with 3,935 shares, decreasing direct ownership by 9% to 40,244 units (SEC Form 4)
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
PRESIDENT AND GENERAL COUNSEL Sardano Michael covered exercise/tax liability with 3,935 shares, decreasing direct ownership by 5% to 74,839 units (SEC Form 4)
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
Director Mccall William H disposed of 325,723 shares (SEC Form 4)
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
Amendment: Director Mccall William H sold $75,400 worth of shares (10,000 units at $7.54), decreasing direct ownership by 50% to 10,000 units (SEC Form 4)
4/A - Sensus Healthcare, Inc. (0001494891) (Issuer)
Sensus Healthcare Inc. SEC Filings
SEC Form 10-K filed by Sensus Healthcare Inc.
10-K - Sensus Healthcare, Inc. (0001494891) (Filer)
Sensus Healthcare Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
Amendment: SEC Form SCHEDULE 13G/A filed by Sensus Healthcare Inc.
SCHEDULE 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)
Sensus Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
Sensus Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
SEC Form 10-Q filed by Sensus Healthcare Inc.
10-Q - Sensus Healthcare, Inc. (0001494891) (Filer)
Sensus Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
Sensus Healthcare Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
SEC Form 10-Q filed by Sensus Healthcare Inc.
10-Q - Sensus Healthcare, Inc. (0001494891) (Filer)
Sensus Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
Sensus Healthcare Inc. Leadership Updates
Live Leadership Updates
Sensus Healthcare Announces Retirement of Director Samuel O'Rear
BOCA RATON, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that Samuel O'Rear will not stand for reelection to the Company's Board of Directors at the Company's 2024 annual meeting of stockholders. Mr. O'Rear has been a Director of Sensus Healthcare since 2012. As previously announced, on January 11, 2024 the Board of Directors of Sensus Healthcare appointed Michael J. Sardano, President and General Counsel of Sensus Healthcare, as a Director, effective today. "Sam has been inv
Sensus Healthcare Prepares Organization for Long-term Growth with Three Promotions
BOCA RATON, Fla, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces the following promotions, all effective immediately: Vice President and General Counsel Michael J. Sardano has been promoted to President and General CounselSales Manager Christopher Machuzak has been promoted to Vice President of Sales for the West CoastSoutheast Regional Sales Manager Jeffrey Starling has been promoted to Vice President of Sales for the East Coast In addition, the Company announces the retirement of Steve Cohen, Executive Vice Pre
Sensus Healthcare Engages Ekpac Healthcare Ltd. as New Exclusive Distributor in China for SRT-100™ Systems
BOCA RATON, Fla., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that it has entered into a new exclusive distribution agreement with Ekpac Healthcare Ltd. to market Sensus SRT-100™ systems in China and Hong Kong. This agreement is effective as of January 1, 2021. Sensus currently has 40 units installed throughout China in public and private hospitals as well as private clinics. It expects this relationship to accelerate SRT-100 unit population in the region. SRT-100 systems utilize S
Sensus Healthcare Inc. Financials
Live finance-specific insights
Sensus Healthcare Reports Fourth Quarter and Full Year 2024 Financial Results
Shipped a record 39 SRT systems during the quarter; revenues of $13.1 million Achieved fifth consecutive quarter of profitability; diluted EPS of $0.09 Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and 12 months ended December 31, 2024. Highlights include the following: Revenues were $13.1 million for the fourth quarter and $41.8 million for the year, up 4% and 71% respectively, compared with the prior year Net income
Sensus Healthcare to Report 2024 Fourth Quarter and Full Year Financial Results and Hold Business Update Conference Call on Wednesday, February 5, 2025
Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report financial results for the 2024 fourth quarter and full year on Wednesday, February 5, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and
REVISED - Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter
This revised news release replaces the one issued on November 14, 2024, contains several non-financial changes throughout and removes the name of and references to a new customer, at the customer's request. The agreement with the new customer remains in effect. Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year ago Expects to have more than 50 IG-SRT Systems signed under the Fair Deal Agreement recurring-revenue program by the end of the year BOCA RATON, Fla, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializin
Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter
Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year agoSigned a Fair Deal Agreement with Platinum Dermatology, a leading dermatology network with 130 clinics across the U.S. Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and nine months ended September 30, 2
Sensus Healthcare to Host Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 14, 2024
BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 14, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones. Participants are encouraged to pre-register for the conference call using this link. Upon registration participants will receive a unique dial-in number that will permit them to bypass
Sensus Healthcare Reports Second Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Second Quarter
Revenues of $9.2 million compares with $4.5 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $2.1 million compares with negative $1.0 million a year ago"Fair Deal Agreement" recurring revenue program gaining momentum with 15 agreements signed to date Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and six months ended June 30, 2024. Highlights from the
Sensus Healthcare Issues Reminder That its Second Quarter 2024 Financial Results and Business Update Conference Call Will be Held on Thursday, August 8, 2024
BOCA RATON, Fla. , Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, reminds investors that management will hold a conference call on Thursday, August 8, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones. Participants are encouraged to pre-register for the conference call using this link. Upon registration participants will receive a unique dial in number that will permit them to
Sensus Healthcare to Host Second Quarter 2024 Financial Results and Business Update Conference Call on Thursday, August 8, 2024
BOCA RATON, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, August 8, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones. Participants are encouraged to pre-register for the conference call using this link. Upon registration participants will receive a unique dial in number that will permit them to bypass the
Sensus Healthcare Reports First Quarter 2024 Financial Results With Revenues up More than Three-fold
Revenues of $10.7 million, compared with $3.4 million in the prior-year quarter; Adjusted EBITDA (a non-GAAP measure) of $3.0 million, compared with negative $2.7 million in the prior-year quarterLaunched the "Fair Deal Agreement" recurring revenue program to provide an equipment placement option and complement the fair market value lease program for SRT systems Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financ
Largest Veterinary Emergency Hospital in Tel Aviv Acquires Sensus Healthcare's SRT-100™ to Provide Gentler Radiotherapy to Treat Tumors in Dogs and Cats
First veterinary commercial sale of the SRT-100 outside the U.S. BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the sale of an SRT-100 system to Chavat Da'at, the Veterinary Specialist Referral Center Knowledge Farm at Beit Verl College in Tel Aviv, to provide a gentler radiotherapy option to treat tumors in dogs and cats. This is the first commercial sale of the SRT-100 for veterinary use outside the U.S. Veterinary Specialist Referral Center Knowledge Farm was establ
Sensus Healthcare Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
SEC Form SC 13G/A filed by Sensus Healthcare Inc. (Amendment)
SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)
SEC Form SC 13G/A filed by Sensus Healthcare Inc. (Amendment)
SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)
SEC Form SC 13G/A filed by Sensus Healthcare Inc. (Amendment)
SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)
SEC Form SC 13G filed by Sensus Healthcare, Inc.
SC 13G - Sensus Healthcare, Inc. (0001494891) (Subject)